Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jill Ann Lindia
Observed names:
J.A. Lindia,
Jill A. Lindia
Observed institution:
Merck & Co., Inc., Rahway, NJ, USA (United States)
OpenAlex ID:
A5113740659
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
2016
·
Antoni Ribas
, Omid Hamid
, et al.
·
JAMA
·
1,069
PDF
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2015
·
Amita Patnaik
, S. Peter Kang
, et al.
·
Clinical Cancer Research
·
808
Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2
2003
·
Catherine Abbadie
, Jill A. Lindia
, et al.
·
Proceedings of the National Academy of Sciences
·
591
PDF
Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Na V 1.9 to sensory transmission and nociceptive behavior
2005
·
Birgit T. Priest
, Beth A. Murphy
, et al.
·
Proceedings of the National Academy of Sciences
·
275
Induction of CX3CL1 Expression in Astrocytes and CX3CR1 in Microglia in the Spinal Cord of a Rat Model of Neuropathic Pain
2005
·
Jill A. Lindia
, Erin McGowan
, et al.
·
Journal of Pain
·
207
PDF
Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats
2005
·
Jill A. Lindia
, Martin G. Köhler
, et al.
·
Pain
·
189
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
2015
·
Adil Daud
, Antoni Ribas
, et al.
·
Journal of Clinical Oncology
·
89
P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma
2015
·
A. Ribas
, J.D. Wolchok
, et al.
·
European Journal of Cancer
·
34
Distribution of the voltage gated sodium channel Nav1.3-like immunoreactivity in the adult rat central nervous system
2003
·
Jill A. Lindia
, Catherine Abbadie
·
Brain Research
·
28
Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules
2014
·
C. Robert
, A.M. Joshua
, et al.
·
Annals of Oncology
·
23
Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.
2015
·
Richard Wayne Joseph
, Tara C. Gangadhar
, et al.
·
Journal of Clinical Oncology
·
7
Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2023
·
Amita Patnaik
, S. Peter Kang
, et al.
Supplementary Tables S1-2, Figure 1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2023
·
Amita Patnaik
, S. Peter Kang
, et al.
Data from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2023
·
Amita Patnaik
, S. Peter Kang
, et al.
Data from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2023
·
Amita Patnaik
, S. Peter Kang
, et al.
Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2023
·
Amita Patnaik
, S. Peter Kang
, et al.
Supplementary Tables S1-2, Figure 1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
2023
·
Amita Patnaik
, S. Peter Kang
, et al.
Show more works
View as search
Works count:
17
Citation count:
3,320
H-index:
10
I10-index:
10
Year
Topic
Type
